Immunohistochemical expression of cyclooxygenase‐2 (COX‐2) in oral nevi and melanoma

Nascimento, Juliana de Souza do; Carlos, Román; Delgado‐Azañero, Wilson; Taylor, Adalberto Mosqueda; Almeida, Oslei Paes de; Romañach, Mário José; Andrade, Bruno Augusto Benevenuto de

doi:10.1111/jop.12385

Cited by 14 publications

(15 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Here we utilised this system to show that, in the context of canine melanoma, COX-2 is required for cellular proliferation, migration and invasion. Previous studies, consistent with our data, have shown that, by immunohistochemical analysis of COX-2, there is a significant association between COX-2 levels and the proliferation status of cells within a tumour cell population (5,7,29,31). Several studies have also revealed the inhibition of COX-2 by NSAIDs and COXIBs leads to a dosedependent reduction in cell proliferation in a range of cancer cell lines (15,(36)(37)(38).…”

Section: Discussionsupporting

confidence: 92%

“…Previously, overexpression of COX-2 has been correlated with the development and progression of human cutaneous melanoma (29,30) and has been proposed as a prognostic marker. In oral melanoma, COX-2 is highly expressed but negative in oral nevi indicating that COX-2 is a valuable marker to distinguish melanocytic lesions of the oral cavity (31), and elevated COX-2 expression is correlated with poor prognosis (32). Similarly, in canine melanoma COX-2 levels are related to Ki-67 proliferation index and survival rate indicating that COX-2 is related to the acquisition of malignancy (7,16,33,34).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

COX-2 Silencing in Canine Malignant Melanoma Inhibits Malignant Behaviour

et al. 2021

View full text Add to dashboard Cite

Metastatic melanoma is a very aggressive form of cancer in both humans and dogs. Dogs primarily develop oral melanoma of mucosal origin. Although oral melanoma in humans is rare, both diseases are highly aggressive with frequent metastases. This disease represents a “One Health” opportunity to improve molecular and mechanistic understanding of melanoma progression. Accumulating evidence suggests that cyclooxygenase-2 (COX-2) may play a critical role in the malignant behaviour of melanoma. In this study we analysed 85 histologically confirmed melanomas from canine patients and showed that COX-2 is overexpressed in both oral and cutaneous melanomas and that COX-2 expression correlates with established markers of poor prognosis. To determine the role of COX-2 in melanoma we developed two melanoma cell lines with stable integration of an inducible doxycycline-regulated expression vector containing a COX-2 targeted micro-RNA (miRNA). Using this system, we showed that cellular proliferation, migration and invasion are COX-2 dependent, establishing a direct relationship between COX-2 expression and malignant behaviour in canine melanoma. We have also developed a powerful molecular tool to aid further dissection of the mechanisms by which COX-2 regulates melanoma progression.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 99%

COX-2 Silencing in Canine Malignant Melanoma Inhibits Malignant Behaviour

et al. 2021

View full text Add to dashboard Cite

show abstract

“…They conclude that differentiation of cyclooxygenase-2 expression in more detail would help to delineate when cyclooxygenase can be defined a negative prognostic factor. Others demonstrated cyclooxygenase-2 to be a useful immunohistochemical marker for the differentiation of melanoma from benign melanocytic lesions in the oral cavity (19). Among others, these observations substantiate findings that suggest cyclooxygenase-2 expression and/or activity as both a pathogenic key player and a promising molecular target in melanoma (20).…”

Section: Cyclooxygenase-2supporting

confidence: 69%

Biomarkers in Malignant Melanoma: Recent Trends and Critical Perspective

Belter

Haase-Kohn

Pietzsch

2017

Cutaneous Melanoma: Etiology and Therapy

View full text Add to dashboard Cite

Abstract:The worldwide incidence of malignant melanoma is steadily increasing, suggesting a probable melanoma "epidemic." From a clinical point of view, malignant melanoma still is an unpredictable disease and, once in the advanced stage, allows only scarce therapeutic options. There is an urgent need to identify, characterize, and validate informative biomarkers, biomarker patterns, or surrogate markers in order to not only improve early diagnosis of melanoma but also for differential diagnosis, staging, prognosis, therapy selection, and therapy monitoring. In this chapter, an update on the ongoing debate on serologic and histologic markers such as lactate dehydrogenase, tyrosinase, S100 family of calcium-binding proteins, cyclooxygenase-2, matrix metalloproteinases, and stem and/or progenitor cell markers are presented, and novel, innovative, and promising trends currently being explored are discussed.

show abstract

“…Furthermore, two studies found that the level of COX-2 in mucoepidermoid carcinoma (MEC) was strongly increased, whereas most of the pleomorphic adenomas and adenoid cystic carcinomas (AdCC) were COX-2-negative [46,47]. In melanomas, Nascimento et al found that oral melanomas were consistently COX-2-positive compared with the benign oral nevi, which were completely COX-2-negative [48]. However, in another study on odontogenic tumors, both the benign and the malignant tumors expressed COX-2, however, the malignant amelocarcinoma specimens exhibited higher levels of COX-2 compared with the benign ameloblastoma samples.…”

Section: Cox-2 Expression In Other Head and Neck Tumorsmentioning

confidence: 99%

Role of Cyclooxygenase-2 in Head and Neck Tumorigenesis

Frejborg

Salo

Salem

2020

IJMS

View full text Add to dashboard Cite

The cyclooxygenase-2 (COX-2) is a potent enzyme that converts arachidonic acid to prostaglandins (PG), including PGE2, a key mediator of inflammation and angiogenesis. Importantly, COX-2 is activated in response to inflammatory stimuli, where it is also believed to promote the development and progression of head and neck cancers (HNC). COX-2 can mediate its protumorigenic effect through various mechanisms, such as inducing cell proliferation, inhibition of apoptosis, and suppressing the host’s immune response. Furthermore, COX-2 can induce the production of vascular endothelial growth factors, hence, promoting angiogenesis. Indeed, the ability of COX-2 inhibitors to selectively restrict the proliferation of tumor cells and mediating apoptosis provides promising therapeutic targets for cancer patients. Thus, in this comprehensive review, we summarized the reported differential expression patterns of COX-2 in different stages of head and neck carcinogenesis—from potentially premalignant lesions to invasive carcinomas. Furthermore, we examined the available meta-analysis evidence for COX-2 role in the carcinogenesis of HNC. Finally, further understanding of the biological processes of COX-2 and its role in orchestrating cell proliferation, apoptosis, and angiogenesis may give therapeutically beneficial insight to develop the management plan of HNC patients and improve their clinical outcomes.

show abstract

Immunohistochemical expression of cyclooxygenase‐2 (COX‐2) in oral nevi and melanoma

Abstract: COX-2 is highly positive in oral melanomas and negative in oral nevi and might represent a useful marker to distinguish melanocytic lesions of the oral cavity.

Cited by 14 publications

References 20 publications

COX-2 Silencing in Canine Malignant Melanoma Inhibits Malignant Behaviour

COX-2 Silencing in Canine Malignant Melanoma Inhibits Malignant Behaviour

Biomarkers in Malignant Melanoma: Recent Trends and Critical Perspective

Role of Cyclooxygenase-2 in Head and Neck Tumorigenesis

Contact Info

Product

Resources

About